LOX Gene: Lysyl Oxidase - Function, Disease Associations, and Clinical Significance
Comprehensive biomedical overview of the LOX gene, encoding lysyl oxidase, a key enzyme in extracellular matrix remodeling, with implications in fibrosis, cancer, and connective tissue disorders.
Gene Information Card
| Symbol | LOX |
|---|---|
| Full Name | Lysyl Oxidase |
| Gene Type | Protein coding |
| Chromosomal Location | 5q23.1 |
| NCBI Gene ID | 4015 ncbi.nlm.nih.gov/gene/4015 |
| Ensembl ID | ENSG00000113083 |
| UniProt ID | P28300 |
| OMIM ID | 153455 |
| HGNC ID | 6664 |
| Aliases | Lysyl oxidase; Protein-lysine 6-oxidase; LOX; MGC105117 |
Description
The LOX gene encodes lysyl oxidase, a copper-dependent amine oxidase that catalyzes the crosslinking of collagen and elastin in the extracellular matrix (ECM). This enzymatic activity is critical for the structural integrity and tensile strength of connective tissues. LOX is synthesized as a 50 kDa proenzyme (pro-LOX) and secreted into the ECM, where it is proteolytically cleaved by bone morphogenetic protein 1 (BMP1) into a functional 32 kDa enzyme and an 18 kDa propeptide (LOX-PP). The active enzyme initiates the formation of covalent crosslinks by oxidizing peptidyl lysine and hydroxylysine residues in collagen, and lysine residues in elastin, to peptidyl alpha-aminoadipic-delta-semialdehyde (allysine). Beyond its structural role, LOX and its propeptide have been implicated in various cellular processes, including cell motility, gene regulation, and tumor suppression or promotion, depending on the cellular context. Dysregulation of LOX expression and activity is associated with fibrotic diseases, cardiovascular disorders, and cancer progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Thoracic Aortic Aneurysm and Dissection | Loss-of-function mutations in LOX impair collagen and elastin crosslinking in the aortic wall, leading to weakened structural integrity, progressive dilation, and risk of dissection. | OMIM: 617168; PubMed: 27105876 |
| Cutis Laxa, Autosomal Recessive, Type 1C | Homozygous or compound heterozygous mutations in LOX result in defective elastin crosslinking, causing loose, sagging skin and other connective tissue abnormalities. | OMIM: 613177; PubMed: 27105876 |
| Cancer (Various, e.g., Breast, Colon, Head and Neck) | LOX is often overexpressed in solid tumors and is associated with hypoxia-induced metastasis. It promotes tumor cell invasion, migration, and pre-metastatic niche formation by remodeling the ECM and activating signaling pathways like FAK and PI3K/AKT. | COSMIC; PubMed: 27105876; PubMed: 21746814 |
| Fibrosis (Pulmonary, Hepatic, Renal) | Elevated LOX expression and activity drive excessive collagen crosslinking and deposition, leading to tissue scarring and organ dysfunction in fibrotic diseases. | PubMed: 21746814; PubMed: 27105876 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Heart | 9.6 | Low |
| Lung | 12.3 | Low |
| Liver | 8.1 | Low |
| Kidney | 10.5 | Low |
| Adipose Tissue | 14.2 | Medium |
| Skin | 18.7 | Medium |
| Aorta | 25.4 | High |
| Uterus | 16.9 | Medium |
| Placenta | 13.8 | Medium |
| Spleen | 6.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (Lung Carcinoma) | 15.3 | Moderate expression; associated with invasive phenotype |
| MCF7 (Breast Adenocarcinoma) | 8.7 | Low expression; increased under hypoxic conditions |
| HepG2 (Hepatocellular Carcinoma) | 7.9 | Low expression |
| HUVEC (Endothelial) | 12.1 | Moderate expression; involved in vascular remodeling |
| BJ (Fibroblast) | 22.5 | High expression; key role in ECM production |
| U2OS (Osteosarcoma) | 11.4 | Moderate expression; linked to bone matrix formation |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.694G>A (p.Gly232Arg) | Missense | Rare (found in familial TAAD) | Loss of function; disrupts copper binding and catalytic activity, impairing crosslinking. |
| c.829C>T (p.Arg277Cys) | Missense | Rare (found in familial TAAD) | Loss of function; affects protein stability and secretion, leading to reduced enzyme activity. |
| c.1003C>T (p.Arg335Ter) | Nonsense | Rare (found in cutis laxa) | Loss of function; premature truncation, likely leading to nonsense-mediated decay and absence of functional protein. |
| c.1123G>A (p.Gly375Ser) | Missense | Rare (found in cutis laxa) | Loss of function; disrupts the active site, reducing catalytic efficiency. |
| c.1186C>T (p.Arg396Trp) | Missense | Rare (found in TAAD) | Loss of function; affects substrate binding and enzyme activity. |
Mutation functional classification
Loss of Function (LOF)
The majority of disease-associated LOX mutations are loss-of-function. These mutations impair the enzyme's catalytic activity, its secretion, or its stability, leading to reduced collagen and elastin crosslinking. This results in weakened connective tissues, as seen in thoracic aortic aneurysm and cutis laxa. In cancer, however, loss of LOX function in the tumor stroma can paradoxically promote tumor progression in some contexts.
Gain of Function (GOF)
Gain-of-function mutations in LOX are not commonly reported in germline disorders. However, somatic copy number gains and transcriptional upregulation (not necessarily mutations) leading to increased LOX expression are frequently observed in various cancers, contributing to metastasis and fibrosis. These are considered functional gains at the expression level rather than activating mutations.
Dominant Negative (DN)
Some missense mutations in LOX may exert a dominant-negative effect. For instance, a mutant LOX monomer could dimerize with a wild-type monomer, resulting in a non-functional heterodimer that is secreted and interferes with normal crosslinking. This mechanism has been proposed for certain TAAD-associated mutations, although haploinsufficiency is also a plausible mechanism.
View complete mutation data:
Gene Ontology (GO)
| • Protein-lysine 6-oxidase activity | • Copper ion binding |
| • Extracellular matrix structural constituent | • Oxidoreductase activity |
| • Scavenger receptor activity | • Extracellular region |
| • Extracellular matrix | • Collagen fibril organization |
| • Elastin metabolic process | • Cellular response to hypoxia |
| • Cell adhesion | • Angiogenesis |
| • Response to oxidative stress |
Pathways
• Collagen biosynthesis and modifying enzymes
• Elastin synthesis
• Extracellular matrix organization
• Integrin signaling pathway
• Hypoxia-inducible factor (HIF) signaling
• TGF-beta signaling pathway
• Focal adhesion pathway
Protein Summary
Lysyl oxidase (LOX) is a 417-amino acid, copper-dependent amine oxidase. It is synthesized as a preproprotein with a signal peptide, a propeptide region (LOX-PP), and a conserved catalytic domain at the C-terminus. The catalytic domain contains the copper-binding site, the lysyl tyrosyl quinone (LTQ) cofactor, and the cytokine receptor-like (CRL) domain. The propeptide is cleaved extracellularly by BMP1 to yield the active enzyme. The active LOX enzyme deaminates lysine and hydroxylysine residues in collagen and elastin, producing allysine, which spontaneously reacts to form crosslinks. LOX-PP, the released propeptide, has its own biological activities, including tumor suppressor functions and regulation of cell differentiation. LOX is secreted and localizes to the ECM, where it plays a structural role. It is also found intracellularly, where it can influence gene transcription. The protein is highly conserved across species.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LOX Knockout HEK293 Cell Line | EDJ-KQ3160 | Human | 4015 | Details Get a Quote |
| ALOX15B Knockout HEK293 Cell Line | EDJ-KQ3377 | Human | 247 | Details Get a Quote |
| ALOX5 Knockout HEK293 Cell Line | EDC07829 | Human | 240 | Details Get a Quote |
| ALOX12 Knockout HEK293 Cell Line | EDJ-KQ4042 | Human | 239 | Details Get a Quote |
| ALOX12B Knockout HEK293 Cell Line | EDC07792 | Human | 242 | Details Get a Quote |
| ALOX15 Knockout HEK293 Cell Line | EDJ-KQ4044 | Human | 246 | Details Get a Quote |
| ALOX5AP Knockout HEK293 Cell Line | EDC07759 | Human | 241 | Details Get a Quote |
| LOXL1 Knockout HEK293 Cell Line | EDJ-KQ5137 | Human | 4016 | Details Get a Quote |
| LOXHD1 Knockout HEK293 Cell Line | EDJ-KQ8786 | Human | 125336 | Details Get a Quote |
| LOXL4 Knockout HEK293 Cell Line | EDJ-KQ10000 | Human | 84171 | Details Get a Quote |
| LOXL3 Knockout HEK293 Cell Line | EDJ-KQ10168 | Human | 84695 | Details Get a Quote |
| ALOXE3 Knockout HEK293 Cell Line | EDC07790 | Human | 59344 | Details Get a Quote |
| LOXL2 Knockout HEK293 Cell Line | EDJ-KQ17787 | Human | 4017 | Details Get a Quote |
| LOXL1 Knockout HCT 116 Cell Line | EDJ-KQ28100 | Human | 4016 | Details Get a Quote |
| LOXL1 Knockout HeLa Cell Line | EDJ-KQ28101 | Human | 4016 | Details Get a Quote |
Displaying Records 1 To 15 Of 59 Records
- 1
- 2
- Next Page »